PPLPHARMA
PIRAMAL PHARMA LIMITED
Each stock's 10,000-path forecast, rendered as light.
PIRAMAL PHARMA LIMITED (PPLPHARMA) Stock Analysis & Case Study
Is PPLPHARMA a good buy? The data-driven verdict.
PIRAMAL PHARMA LIMITED (PPLPHARMA) trades at ₹208,on the numbers it tread carefully, a Downstox Snapshot Score of 38/100.
On the numbers, PIRAMAL PHARMA LIMITED (PPLPHARMA) tread carefully, a Downstox Snapshot Score of 38/100, weighing expensive at 61.4× earnings, ROE of -3.8%, a 54% model probability of trading higher in a year. Below: the full bull case, bear case, sector-relative valuation, and a probability-weighted price target for 2027-2031.
Last updated . Data snapshot for research, not investment advice.
PPLPHARMA fundamentals at a glance, PE, PB, ROE, ROCE, market cap, dividend yield
How PPLPHARMA ranks against the 2,373 companies in our screener
- PPLPHARMA's market cap of 27,898 Cr ranks in the 87th percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- PPLPHARMA's book value of ₹61 ranks in the 38th percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- PPLPHARMA's promoter holding of 34.8% ranks in the 12th percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- PPLPHARMA's 3-year profit (PAT) growth of -31.0% ranks in the 6th percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- PPLPHARMA's 3-year revenue growth of 8.0% ranks in the 44th percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- PPLPHARMA's debt-to-equity ratio of 0.70x is lower than 24% of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
Is PPLPHARMA overvalued? PPLPHARMA P/E vs peers
PPLPHARMA trades at 61.4× earnings. We don't have a verified sector peer group for this stock yet, so no sector peer median or peer comparison table is shown here. Showing one anyway would compare it against an arbitrary set of large-cap names, not real sector peers.
PPLPHARMA share price target 2027, 2028, 2029, 2030, 2031, a probability view
Unlike a single guessed number, this is a probability-weighted range from a 10,000-path Monte-Carlo simulation on 3.7y of PPLPHARMA history (3%/yr drift, 41%/yr volatility).
| Year | Low (P10) | Median target (P50) | High (P90) | Upside vs today |
|---|---|---|---|---|
| PPLPHARMA 2027 | ₹129 | ₹217 | ₹365 | +4% |
| PPLPHARMA 2028 | ₹107 | ₹225 | ₹470 | +7% |
| PPLPHARMA 2029 | ₹94 | ₹233 | ₹576 | +11% |
| PPLPHARMA 2030 | ₹84 | ₹241 | ₹692 | +15% |
| PPLPHARMA 2031 | ₹77 | ₹250 | ₹805 | +19% |
Median (P50) is the central estimate; the P10-P90 band is the 80% confidence range. Probabilities, not promises.
What is the probability PPLPHARMA goes up, or doubles?
The bull case for PPLPHARMA
- PIRAMAL PHARMA LIMITED is part of the nifty200 universe with live, tracked fundamentals on Downstox.
- Upside scenario: the model's optimistic (P90) 3-year path reaches ₹576.
The bear case & risks
- PPLPHARMA's P/E of 61.4x is lower than 20% of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- Downside scenario: the model's pessimistic (P10) 3-year path falls to ₹94.
PPLPHARMA volatility & expected range, how bumpy is the ride?
Over the last 3.7 years PPLPHARMA compounded at 3%/year with annualized volatility of 41%. That volatility implies a 1-year 80% range of ₹129-₹365, the honest backbone behind any single price target.
PPLPHARMA price forecast, the full 60-month probability fan
PPLPHARMA price probability fan
Each band shows where 10,000 simulated paths land. The wider the fan, the more uncertainty.
Probability of key outcomes
What are the odds PPLPHARMA hits common targets within the simulated horizon?
Full multi-horizon detail on the PPLPHARMA price target & forecast page.
PPLPHARMA Piotroski F-Score: 4/8, how financially strong is it?
The Piotroski F-Score grades financial strength on profitability, leverage and efficiency checks. Downstox scores the eight checks it can verify from published filings, so 8 is full marks. PPLPHARMA scores 4/8, mixed financial health.
PPLPHARMA MTF margin & leverage across 10 brokers
Margin Trading Facility lets you buy PPLPHARMA with part of the capital. Lower margin % = higher leverage. Rates compared across 10 brokers (no competitor publishes this):
| Broker | Margin required | Approx. leverage |
|---|---|---|
| Upstox | 32.50% | 3.1× |
| Zerodha | 32.46% | 3.1× |
| Groww | 32.58% | 3.1× |
| DhanCHEAPEST | 32.46% | 3.1× |
| Kotak Neo | 32.47% | 3.1× |
| Paytm Money | 32.72% | 3.1× |
| Pocketful | 32.48% | 3.1× |
| Anand Rathi | 32.46% | 3.1× |
| Bajaj Broking | 33.00% | 3.0× |
| Share India | 32.56% | 3.1× |
Compare every broker on the PPLPHARMA MTF page.
About PIRAMAL PHARMA LIMITED: sector, index & market-cap context
PIRAMAL PHARMA LIMITED (PPLPHARMA) is a mid-cap NSE-listed company, and a constituent of the Nifty 500 index, with a market capitalisation of ₹27,762 Cr. See more stocks on our screener.
How the PPLPHARMA Snapshot Score & forecast are built
The Downstox Snapshot Score is a transparent, rules-based read of PIRAMAL PHARMA LIMITED's public fundamentals plus a statistical forecast, not an analyst opinion. It rewards low-to-fair valuation, high ROE/ROCE, a strong Piotroski F-Score, a dividend, low volatility and a favourable probability of upside; it penalises rich valuations, weak capital efficiency, a low F-Score and high volatility. The price target is a 10,000-path Monte-Carlo simulation on real historical volatility, a distribution, not a single guess. The bull and bear cases are generated from the same data, so you always see both sides.
This is information, not investment advice. Do your own due diligence and consult a SEBI-registered adviser before investing.
PPLPHARMA analysis, FAQs
Is PIRAMAL PHARMA LIMITED (PPLPHARMA) a good buy?
On the numbers, PIRAMAL PHARMA LIMITED (PPLPHARMA) tread carefully, a Downstox Snapshot Score of 38/100, weighing expensive at 61.4× earnings, ROE of -3.8%, a 54% model probability of trading higher in a year. This is a data snapshot for research, not investment advice.
Is PPLPHARMA overvalued or undervalued?
PPLPHARMA trades at 61.4× earnings, expensive versus the ~22× long-run Nifty average.
What is the PPLPHARMA share price target for 2031?
PPLPHARMA's probability-weighted 2031 median target is ₹250, with an 80% range of ₹77-₹805 (10,000-path Monte-Carlo).
What is the probability PPLPHARMA doubles in 5 years?
The modelled probability of PPLPHARMA reaching ₹419 (2×) within 5 years is 29%.
What is the bull case for PPLPHARMA?
PIRAMAL PHARMA LIMITED is part of the nifty200 universe with live, tracked fundamentals on Downstox.
What are the risks in PPLPHARMA?
PPLPHARMA's P/E of 61.4x is lower than 20% of the 2,373 NSE companies in our screener, as of 9 Aug 2026.